A pilot study on the detection of microsatellite instability using long mononucleotide repeats in solid tumors
- Authors:
- Published online on: July 22, 2024 https://doi.org/10.3892/ol.2024.14578
- Article Number: 445
-
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Microsatellite instability (MSI) status is a prognostic biomarker for immunotherapy in certain types of cancers, such as colorectal cancers (CRCs) and endometrial cancers (ECs). Tumors that are categorized as having high MSI (MSI‑H) express high levels of neoantigens for immune recognition. The typical MSI test measures the length of short mononucleotide repeats (SMR) poly(A) 21‑27; however, a limitation of this test is the difficulty in determining the shift size, particularly in endometrial cancer. To investigate an MSI detection assay with improved performance, the present study analyzed the use of poly(A) 40‑44 mononucleotide repeats to detect the MSI status of 100 patients with either CRC (n=50) or EC (n=50). Capillary electrophoresis was used to evaluate five long mononucleotide repeat (LMR) markers, including poly(A) 40‑A, 40‑B, 40‑C, 40‑D and 44. The concordance rate of the LMR‑MSI assay compared with an immunohistochemistry MSI detection assay was 96.0 and 95.1% for CRCs and ECs respectively, with the detection limit of the LMR‑MSI assay demonstrated to be 2.5% MSI‑H in HCT116 colorectal carcinoma cell lines. The LMR‑MSI assay yielded a 95.1% concordance rate in ECs compared with that in the SMR‑MSI test (87.8%). The LMR‑MSI test identified a significantly higher mean shift size (13 bp) in MSI‑H tumors compared with the SMR‑MSI test (10 bp), in both EC and CRC tissue samples. Together, the present study suggested that the LMR‑MSI test could potentially be a sensitive and practical technology for molecular laboratory testing, particularly in the use of immunotherapy for patients with CRCs and ECs.
